Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Transcriptional Landscape of the Microenvironment in Bone Marrow Fibrosis at Single Cell Level

Nils B. Leimkühler, Ronghui Li, MSc, Helene Gleitz, PhD, Inge Snoeren, MSc, Stijn Fuchs, Martina Crysandt, MD, Steffen Koschmieder, Christoph Kuppe, MD, Guntram Buesche, MD, Hans H Kreipe, MD PhD, Ivan Costa, PhD, Rafael Kramann, MD PhD, Rebekka K. Schneider, MD PhD

Blood (2019) 134 (Supplement_1): 1675.

https://doi.org/10.1182/blood-2019-126897

Published: 2019

Journal Articles

Synergy between FLT3-ITD and p53 Haploinsufficiency or Loss in the Development of Acute Myeloid Leukemia

Zengkai Pan, MD PhD, Min Yang, Kezhi Huang, MD PhD, Guntram Buesche, MD, Gudrun Göhring, MD, Michaela Scherr, PhD, Matthias Gaestel, PhD, Matthias Eder, MD, Julia Skokowa, MDPhD, Jianfeng Zhou, PhD, Karl Welte, Li-Gen Liu, MD, Arnold Ganser, MD, Zhixiong Li, MD

Blood (2018) 132 (Supplement 1): 771.

https://doi.org/10.1182/blood-2018-99-110770

Published: 2018

Journal Articles

Changes of the Niche of Erythropoiesis Appear to Contribute to Severe Transfusion-Dependent Anemia in a Significant Proportion of Patients with Myelodysplastic Syndromes

Guntram Buesche, MD, Aristoteles Giagounidis, MD PhD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD Prof., Arnold Ganser, MD, Carlo Aul, MD, Hans Heinrich Kreipe, MD

Blood (2015) 126 (23): 4114.

https://doi.org/10.1182/blood.V126.23.4114.4114

Published: 2015

Journal Articles

The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFB-MYH11

Kezhi Huang, Min Yang, Zengkai Pan, Florian H. Heidel, MD, Michaela Scherr, PhD, Matthias Eder, MD, Thomas Fischer, MD, Guntram Buesche, MD, Nils von Neuhoff, PhD, Arnold Ganser, MD, Zhixiong Li, MD

Blood (2015) 126 (23): 1383.

https://doi.org/10.1182/blood.V126.23.1383.1383

Published: 2015

Journal Articles

Accelerated Telomere Shortening Identifies a Subgroup of Patients with Myelodysplastic Syndrome and Isolated 5q Minus Deletion with a Higher Probability of Response to Lenalidomide Treatment

Fabian Beier, MD, Ralph P Schneider, MS, Guntram Buesche, MD, Jens Panse, MD, Ulrich Germing, Maria A Blasco, PhD, Tim H Brümmendorf

Blood (2012) 120 (21): 3809.

https://doi.org/10.1182/blood.V120.21.3809.3809

Published: 2012

Journal Articles

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Guntram Buesche, MD, Aristoteles Giagounidis, MD, Gudrun Göhring, Brigitte Schlegelberger, Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2012) 120 (21): 2826.

https://doi.org/10.1182/blood.V120.21.2826.2826

Published: 2012

Journal Articles

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Guntram Buesche, M.D., Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2011) 118 (21): 3819.

https://doi.org/10.1182/blood.V118.21.3819.3819

Published: 2011

Journal Articles

Retroviral Ectopic Expression of a Signaling-Defective Thrombopoietin Receptor (Mpl) Induces a Systemic Loss of Hematopoietic Stem Cells in Mice,

Sabine Wintterle, MD, Dirk Heckl, PhD, Adrian Schwarzer, MD, Guntram Buesche, MD, Christopher Baum, MD, Ute Modlich, DVM, PhD

Blood (2011) 118 (21): 4175.

https://doi.org/10.1182/blood.V118.21.4175.4175

Published: 2011

Journal Articles

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Guntram Buesche, MD, Stephanie Dieck, Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Robert Knight, MD, Carlo Aul, MD, Hans Kreipe, MD

Blood (2009) 114 (22): 3800.

https://doi.org/10.1182/blood.V114.22.3800.3800

Published: 2009

Journal Articles

Coincidence of bcr/abl-Positive Chronic Myeloid Leukemia and bcr/abl-Negative Chronic Myeloproliferative Disorder and Its Relevance to the Course of Disease.

Guntram Buesche, Oliver Bock, Kais Hussein, Nils von Neuhoff, Brigitte Schlegelberger, Hans H. Kreipe

Blood (2007) 110 (11): 2950.

https://doi.org/10.1182/blood.V110.11.2950.2950

Published: 2007

Journal Articles

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2 V617F mutation

Kais Hussein, Oliver Bock, Anna Seegers, Michael Flasshove, Felicitas Henneke, Guntram Buesche, Hans Heinrich Kreipe

Blood (2007) 109 (9): 4106–4107.

https://doi.org/10.1182/blood-2006-12-061135

Published: 2007

Journal Articles

In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.

Guntram Buesche, Rudiger Hehlmann, Arnold Ganser, Hartmut Hecker, Andreas Hochhaus, Hermann Heimpel, Barbara Heinze, Claudia Schoch, PD., Dorothea Gadzicki, Martin Mueller, Nils von Neuhoff, Susanne Schnittger, PD., Brigitte Schlegelberger, Bernd Frye, Axel Georgii, Hans Kreipe

Blood (2006) 108 (11): 2195.

https://doi.org/10.1182/blood.V108.11.2195.2195

Published: 2006

Journal Articles

Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.

Guntram Buesche, Ruediger Hehlmann, Arnold Ganser, Hartmut Hecker, Mathias Freund, Hermann Heimpel, Barbara Heinze, Dorothea Gadzicki, Brigitte Schlegelberger, Christa Fonatsch, Bernd Frye, Andreas Tobler, Axel Georgii, Hans H. Kreipe

Blood (2005) 106 (11): 1106.

https://doi.org/10.1182/blood.V106.11.1106.1106

Published: 2005

Journal Articles

Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.

Guntram Buesche, Stephanie Dieck, Aristoteles Giagounidis, Oliver Bock, Ludwig Wilkens, PD, Brigitte Schlegelberger, Robert Knight, John Bennett, Carlo Aul, Hans H. Kreipe

Blood (2005) 106 (11): 372.

https://doi.org/10.1182/blood.V106.11.372.372

Published: 2005

Journal Articles

Marrow Fibrosis in Myelodysplastic Syndromes - Its Significance in the Context of the WHO Classification of Disease and the International Prognostic Scoring System.

Guntram Buesche, Arnold Ganser, Ludwig Wilkens, PD., Brigitte Schlegelberger, Hartmut Hecker, Axel Georgii, Hans H. Kreipe

Blood (2004) 104 (11): 1446.

https://doi.org/10.1182/blood.V104.11.1446.1446

Published: 2004

NARROW

Transcriptional Landscape of the Microenvironment in Bone Marrow Fibrosis at Single Cell Level

Synergy between FLT3-ITD and p53 Haploinsufficiency or Loss in the Development of Acute Myeloid Leukemia

Changes of the Niche of Erythropoiesis Appear to Contribute to Severe Transfusion-Dependent Anemia in a Significant Proportion of Patients with Myelodysplastic Syndromes

The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFB-MYH11

Accelerated Telomere Shortening Identifies a Subgroup of Patients with Myelodysplastic Syndrome and Isolated 5q Minus Deletion with a Higher Probability of Response to Lenalidomide Treatment

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Retroviral Ectopic Expression of a Signaling-Defective Thrombopoietin Receptor (Mpl) Induces a Systemic Loss of Hematopoietic Stem Cells in Mice,

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Coincidence of bcr/abl-Positive Chronic Myeloid Leukemia and bcr/abl-Negative Chronic Myeloproliferative Disorder and Its Relevance to the Course of Disease.

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2 V617F mutation

In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.

Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.

Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.

Marrow Fibrosis in Myelodysplastic Syndromes - Its Significance in the Context of the WHO Classification of Disease and the International Prognostic Scoring System.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only